JB Chemicals & Pharmaceuticals

JB Pharma delivered a strong Q3 FY26 with revenue of INR 1,065 CrCurrent reported value: INR 1,065 Cr. No comparable prior figure is available in the source record. (+11Current reported value: 11. No comparable prior figure is available in the source record.% YoY), EBITDA of INR 305 CrCurrent reported value: INR 305 Cr. No comparable prior figure is available in the source record. (+13% YoY), and PAT of INR 198 CrCurrent reported value: INR 198 Cr. No comparable prior figure is available in the source record. (+22Current reported value: 22. No comparable prior figure is available in the source record.% YoY). Domestic business grew 10%Current 10%. Reported change: +10% YoY. to INR 620 Cr, outperforming IPM growth of 9% (IQVIA Dec 2025). International formulations surged 20%Current 20%. Reported change: +20% YoY. to INR 306 Cr, driven by Russia, South Africa, and US. Gross margins expanded 200 bps to 69.1%Current 69.1%. Reported change: +200 bps YoY. on better mix and stable RM costs. EBITDA margin improved 60 bps to 28.7%Current reported value: 28.7%. No comparable prior figure is available in the source record.. Management reiterated FY26 EBITDA margin guidance of 27-29% and expects domestic growth to exceed IPM by 200-300 bps. International business is guided to high single-digit growth for FY26. Key risk: slowdown in acute gastro portfolio impacting domestic growth trajectory.